We are live on !
Find out more
Corriente Advisors Portfolio holdings
AUM
$9.5M
Turnover
83.33%
1-Year Est. Return
805.26%
This Fund
S&P 500
This Quarter Est. Return
+82.51%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
+$61.7M
(+67%)
Cap. Flow
+$20.3M
Cap. Flow % of AUM
Cap. Flow %
13.14%
Top 10 Holdings %
Top 10 Hldgs %
95.94%
Holding
21
New
10
Increased
1
Reduced
4
Closed
5
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sonos
SONO
|
+$16.7M |
| 2 |
uniQure
QURE
|
+$10.6M |
| 3 |
Replimune Group
REPL
|
+$8.58M |
| 4 |
Ocular Therapeutix
OCUL
|
+$4.77M |
| 5 |
MAXR
Maxar Technologies
MAXR
|
+$2.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals
RETA
|
+$6.46M |
| 2 |
Palvella Therapeutics
PVLA
|
+$4.42M |
| 3 |
Cue Biopharma
CUE
|
+$3.86M |
| 4 |
EPZM
Epizyme
EPZM
|
+$3.57M |
| 5 |
Schrodinger
SDGR
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.68% |
| 2 | Technology | 36.99% |
| 3 | Consumer Discretionary | 1.4% |
| 4 | Materials | 0.59% |
| 5 | Real Estate | 0.34% |
Similar funds
SCM
Corriente Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Corriente Advisors held 21 positions worth $154M, up 67% from $92.6M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Corriente Advisors deployed $20.3M of net new capital in Q2 2020, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Sonos: 1,570,000 shares worth $23M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 75% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Reata Pharmaceuticals, an estimated $6.46M trimmed.
- Corriente Advisors's largest Q2 2020 buy was Sonos: 1,570,000 shares worth $23M.
- Corriente Advisors added most to Maxar Technologies in Q2 2020, an estimated $2.73M increase.
- Corriente Advisors's biggest Q2 2020 reduction was Reata Pharmaceuticals, cutting an estimated $6.46M.
- Corriente Advisors fully exited Epizyme in Q2 2020, selling an estimated $3.57M.
- Corriente Advisors's ten largest holdings make up 96% of its $154M portfolio in Q2 2020.
- Corriente Advisors opened 10 new positions and closed 5 in Q2 2020.
- Corriente Advisors's portfolio value rose 67% quarter-over-quarter to $154M.
Based on Corriente Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.